H W Suh, Y H Kim, Y S Choi, D K Song
Index: Peptides 16(7) , 1229-34, (1995)
Full Text: HTML
Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick response induced by ICV-administered morphine (2 micrograms). beta-endorphin (1 microgram), and U50,488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]benzeocetamide), 60 micrograms). However, ICV pretreatment with CCK-8s was not effective in reducing the inhibition of the tail flick response induced by [D-Pen(2)-D-Pen5]enkephalin (DPDPE; 10 micrograms) administered ICV. To determine what subtype(s) of CCK receptors are involved in antagonizing the antinociception induced by these opioids, effect of lorglumide sodium salt (a CCKA receptor antagonist) or PD135,158 N-methyl-D-glucamine salt (a CCKB receptor antagonist) on opioid-induced inhibition of the tail flick response was examined. Various doses of lorglumide sodium salt (lorglumide) or PD135,158 N-methyl-D-glucamine salt (PD135,158) injected ICV alone did not affect the basal tail flick response. The antagonistic effect of CCK-8s on morphine-, beta-endorphin-, and U50,488H-induced inhibition of the tail flick response was blocked in a dose-dependent manner by the co-ICV injection of PD135,158 (0.001-0.1 ng). The co-ICV injection of lorglumide (0.001-0.1 ng) dose-dependently blocked the antagonistic effect of CCK-8s on beta-endorphin- and U50,488H-induced, but not morphine-induced, inhibition of the tail flick response. Our results suggest that both CCKA and CCKB receptors are involved in antagonizing antinociception induced by beta-endorphin and U50,488H administered supraspinally. However, only CCKB (but not CCKA) receptors are involved in antagonizing antinociception induced by morphine administered supraspinally. CCK receptors are not involved in antagonizing the supraspinally administered DPDPE-induced antinociception.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Lorglumide sodium salt
CAS:1021868-76-7 |
C22H31Cl2N2NaO4 |
Different downstream signalling of CCK1 receptors regulates ...
2015-11-01 [Br. J. Pharmacol. 172 , 5050-67, (2015)] |
Expression of the transcription factor Egr-1 in pancreatic a...
2014-01-01 [Cell Physiol. Biochem. 33(5) , 1411-25, (2014)] |
Identification of N-arachidonylglycine, U18666A, and 4-andro...
2005-08-05 [Biochem. Biophys. Res. Commun. 333(3) , 778-86, (2005)] |
Pharmacological properties of lorglumide as a member of a ne...
1987-11-01 [Arzneimittelforschung 37 , 1265-1268, (1987)] |
Studies of three non-peptide cholecystokinin antagonists (de...
1991-02-01 [Br. J. Pharmacol. 102 , 391-395, (1991)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved